Department of Physiology and Cell Biology, The Ohio State University, 304 Hamilton Hall, 1645 Neil Ave., Columbus, OH 43210-1218, United States.
Pharmacol Ther. 2013 Oct;140(1):53-80. doi: 10.1016/j.pharmthera.2013.05.011. Epub 2013 Jun 2.
Although epidemiological studies provide strong evidence for an inverse relationship between omega-3 polyunsaturated fatty acids (n-3 PUFAs) and cardiac mortality, inconsistent and often conflicting results have been obtained from both animal studies and clinical prevention trials. Despite these heterogeneous results, some general conclusions can be drawn from these studies: 1) n-PUFAs have potent effects on ion channels and calcium regulatory proteins that vary depending on the route of administration. Circulating (acute administration) n-3 PUFAs affect ion channels directly while incorporation (long-term supplementation) of these lipids into cell membranes indirectly alter cardiac electrical activity via alteration of membrane properties. 2) n-3 PUFAs reduce baseline HR and increase HRV via alterations in intrinsic pacemaker rate rather than from changes in cardiac autonomic neural regulation. 3) n-3 PUFAs may be only effective if given before electrophysiological or structural remodeling has begun and have no efficacy against atrial fibrillation. 5) Despite initial encouraging results, more recent clinical prevention and animal studies have not only failed to reduce sudden cardiac death but actually increased mortality in angina patients and increased rather than decreased malignant arrhythmias in animal models of regional ischemia. 6) Given the inconsistent benefits reported in clinical and experimental studies and the potential adverse actions on cardiac rhythm noted during myocardial ischemia, n-3 PUFA must be prescribed with caution and generalized recommendations to increase fish intake or to take n-3 PUFA supplements need to be reconsidered.
尽管流行病学研究为ω-3 多不饱和脂肪酸(n-3PUFAs)与心脏死亡率之间的反比关系提供了有力证据,但动物研究和临床预防试验的结果却不一致且常常相互矛盾。尽管这些结果存在异质性,但从这些研究中可以得出一些普遍结论:1)n-PUFAs 对离子通道和钙调节蛋白具有强大的影响,具体影响因给药途径而异。循环(急性给药)n-3PUFAs 直接影响离子通道,而这些脂质掺入(长期补充)细胞膜则通过改变膜性质间接改变心脏电活动。2)n-3PUFAs 通过改变固有起搏率降低静息心率并增加心率变异性,而不是通过改变心脏自主神经调节。3)n-3PUFAs 可能只有在电生理或结构重塑开始之前给予才有效,并且对心房颤动无效。5)尽管最初的结果令人鼓舞,但最近的临床预防和动物研究不仅未能降低心脏性猝死的发生率,反而在心绞痛患者中增加了死亡率,并在局部缺血的动物模型中增加而不是减少恶性心律失常。6)鉴于临床和实验研究报告的益处不一致,以及在心肌缺血期间注意到对心脏节律的潜在不利影响,n-3PUFA 的使用必须谨慎,并需要重新考虑增加鱼类摄入量或服用 n-3PUFA 补充剂的一般性建议。